Insightec, a trailblazing medical technology company based in Miami, has achieved a major milestone with the FDA’s approval of its Exablate Neuro platform for treating advanced Parkinson’s Disease. This non-invasive treatment uses focused ultrasound guided by MRI to precisely target areas of the brain responsible for motor symptoms, without the need for incisions or implants.
The latest approval allows for staged bilateral procedures, meaning both sides of the brain can now be treated in separate sessions. This is a significant advancement for patients who previously had limited options when medications failed to control their symptoms.
With over 25,000 patients treated globally, Insightec’s technology is reshaping the future of neurosurgery. CEO Maurice R. Ferré emphasized the importance of expanding access to this life-changing therapy, calling it a “new era” for those living with Parkinson’s.
This development not only highlights Miami’s growing role in health tech innovation but also brings renewed hope to patients and families affected by this challenging condition.